Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Samson, Adel , Scott, Karen J. , Taggart, David J. , Wilson, Erica , Nuovo, Gerard J. , Thomson, Simon , Mathew, Ryan , Fuller, Martin, Kottke, Timothy, Thompson, Jill , Ilett, Elizabeth J. , Cockle, Julia , Hille, Philip van, Sivakumar, Gnanamurthy, Polson, Euan S. , Turnbull, Samantha , Appleton, Elizabeth , Migneco, G , Rose, Ailsa , Coffey, Matthew, Beirne, Deborah , Collinson, Fiona , Ralph, Christy , Anthoney, Alan , Twelves, Christopher , Furness, Andrew J.S. , Quezada, Sergio A. , Wurdak, Heiko , Errington‐Mais, Fiona , Pandha, Hardev , Harrington, Kevin J. , Selby, Peter J. , Vile, Richard G. , Griffin, Stephen , Stead, Lucy F. , Short, Susan , Melcher, Alan , Taggart, David , Wilson, Erica , Nuovo, Gerard J , Thomson, Simon , Mathew, Ryan K , Kottke, Timothy J, Thompson, Jill M, Ilett, Elizabeth J , Cockle, Julia V , Turnbull, Samantha J , Rose, Ailsa S , Beirne, Deborah A , Ralph, Christy , Alan Anthoney, D , Quezada, Sergio A , Wurdak, Heiko , Errington-Mais, Fiona , Selby, Peter J , Griffin, Stephen , Stead, Lucy F , Short, Susan C , Melcher, Alan A , Harrington, Kevin , West, Emma J. , Corns, Robert A. , Appleton, Elizabeth

Mayo Clinic

Science Translational Medicine | January 3, 2018 | Volume: 10 | Issue: 422 | Pages: No page available

10.1126/scitranslmed.aam7577 | PMID 29298869 Get It

Intravenous infusion of oncolytic reovirus in patients leads to infection of brain tumors, infiltration by cytotoxic T cells, and up-regulation of PD-L1.
Genital vibration for sexual function and enhancement: a review of evidence
Rullo, Jordan , Lorenz, Tierney K. , Ziegelmann, Matthew , Meihofer, Laura, Herbenick, Debby , Rullo, Jordan E, Lorenz, Tierney , Ziegelmann, Matthew J, Faubion, Stephanie S.

Mayo Clinic

Sexual and Relationship Therapy | January 2, 2018 | Volume: 33 | Issue: 3 | Pages: 263-274

10.1080/14681994.2017.1419557 | PMID 33223960 Get It

Reconstruction of the hip after resection of periacetabular oncological lesions
Brown, Timothy S. , Salib, Christopher G. , Rose, Peter S. , Sim, Franklin H. , Lewallen, David G. , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | January 1, 2018 | Volume: 100-B | Issue: 1_Supple_A | Pages: 22-30

10.1302/0301-620x.100b1.bjj-2017-0548.r1 | PMID 29292336 Get It

AimsReconstruction of the acetabulum after resection of a periacetabular malignancy is technically challenging and many different techniques have been used with varying success. Our aim was to prepare a systematic review of the literature dealing with these techniques in order to clarify the management, the rate of complications and the outcomes.Patients and MethodsA search of PubMed and MEDLINE was conducted for English language articles published between January 1990 and February 2017 with combinations of key search terms to identify studies dealing with periacetabular resection with reconstruction in patients with a malignancy. Studies in English that reported radiographic or clinical outcomes were included. Data collected from each study included: the number and type of reconstructions, the pathological diagnosis of the lesions, the mean age and follow-up, gender distribution, implant survivorship, complications, functional outcome, and mortality. The results from individual studies were combined for the general analysis, and then grouped according to the type of reconstruction.ResultsA total of 57 studies met the inclusion criteria and included 1700 patients. Most lesions were metastatic (41%), followed by chondrosarcoma (29%), osteosarcoma (10%), Ewing’s sarcoma (7%), and multiple myeloma (2%). The techniques of reconstruction were divided into seven types for analysis: those involving a Harrington reconstruction, a saddle prosthesis, an allograft and allograft prosthesis composite, a pasteurised autograft, a porous tantalum implant, a custom-made prosthesis and a modular hemipelvic reconstruction. The rate of complications was 50%, with infection (14%) and instability (8%) being the most common. Mortality data were available for 1427 patients (84%); 50% had died of disease progression, 23% were alive with disease, and 27% had no evidence of disease at a mean follow-up of 3.4 years (0 to 34).ConclusionBoth the rate of complications and mortality are high following resection of oncological periacetabular lesions and reconstruction. Many types of reconstruction have been used with unique challenges and complications for each technique. Newer prostheses, including custom-made prostheses and porous tantalum implants and augments, have shown promising early functional and radiographic outcomes. Cite this article: Bone Joint J 2018;100-B(1 Supple A):22–30.
Circulating levels of monocyte chemoattractant protein‐1 as a potential measure of biological age in mice and frailty in humans
Yousefzadeh, Matthew J. , Schafer, Marissa , Hooten, Nicole Noren , Atkinson, Elizabeth J. , Baker, Darren J. , Quarles, Ellen , Robbins, Paul D. , Niedernhofer, Laura J. , Schafer, Marissa J, Niedernhofer, Laura J , Robbins, Paul D , Baker, Darren J , Schafer, Marissa J , Evans, Michele K. , Ladiges, Warren , LeBrasseur, Nathan K.

Mayo Clinic

Aging Cell | December 31, 2017 | Volume: 17 | Issue: 2 | Pages: No page available

10.1111/acel.12706 | PMID 29290100 Get It

Summary A serum biomarker of biological versus chronological age would have significant impact on clinical care. It could be used to identify individuals at risk of early‐onset frailty or the multimorbidities associated with old age. It may also serve as a surrogate endpoint in clinical trials targeting mechanisms of aging. Here, we identified MCP ‐1/ CCL 2, a chemokine responsible for recruiting monocytes, as a potential biomarker of biological age. Circulating monocyte chemoattractant protein‐1 ( MCP ‐1) levels increased in an age‐dependent manner in wild‐type ( WT ) mice. That age‐dependent increase was accelerated in Ercc1 −/Δ and Bubr1 H/H mouse models of progeria. Genetic and pharmacologic interventions that slow aging of Ercc1 −/Δ and WT mice lowered serum MCP ‐1 levels significantly. Finally, in elderly humans with aortic stenosis, MCP ‐1 levels were significantly higher in frail individuals compared to nonfrail. These data support the conclusion that MCP ‐1 can be used as a measure of mammalian biological age that is responsive to interventions that extend healthy aging.
Prophylactic Platelet Transfusions for Critically Ill Patients With Thrombocytopenia: A Single-Institution Propensity-Matched Cohort Study
Frank, Ryan D. , Kor, Daryl J. , Warner, Matthew A. , Chandran, Arun Kumar

Mayo Clinic

Anesthesia & Analgesia | December 30, 2017 | Volume: 128 | Issue: 2 | Pages: 288-295

10.1213/ane.0000000000002794 | PMID 29293185 Get It

BACKGROUND: Thrombocytopenia is frequently encountered in critically ill patients, often resulting in prophylactic transfusion of platelets for the prevention of bleeding complications. However, the efficacy of this practice remains unclear. The objective of this study was to determine the relationship between prophylactic platelet transfusion and bleeding complications in critically ill patients. METHODS: This is a retrospective cohort study of adults admitted to surgical, medical, or combined medical-surgical intensive care units (ICUs) at a single academic institution between January 1, 2009, and December 31, 2013. Inclusion criteria included age ≥18 years and a platelet count measured during ICU admission. Propensity-matched analyses were used to evaluate associations between prophylactic platelet transfusions and the outcomes of interest with a primary outcome of red blood cell transfusion in the ensuing 24 hours and secondary outcomes of ICU and hospital-free days and changes in sequential organ failure assessment scores. RESULTS: A total of 40,693 patients were included in the investigation with 3227 (7.9%) receiving a platelet transfusion and 1065 (33.0%) for which platelet transfusion was prophylactic in nature. In propensity-matched analyses, 994 patients with prophylactic platelet transfusion were matched to those without a transfusion. Patients receiving prophylactic platelets had significantly higher red blood cell transfusion rates (odds ratio 7.5 [5.9–9.5]; P < .001), fewer ICU-free days (mean [standard deviation] 20.8 [9.1] vs 22.7 [8.3] days; P = .004), fewer hospital-free days (13.0 [9.7] vs 15.8 [9.4] days; P < .001), and less improvement in sequential organ failure assessment scores (mean decrease of 0.2 [3.6] vs 1.8 [3.3]; P < .001) in the subsequent 24 hours. These findings appeared robust, persisting in multiple predefined sensitivity analyses. CONCLUSIONS: Prophylactic administration of platelets in the critically ill was not associated with improved clinical outcomes, though residual confounding may exist. Further investigation of platelet transfusion strategies in this population is warranted.
Predictors of Urology Resident Surgical Skills, Clinical Communication Skills, Common Sense and In-Service Scores
Thompson, R. Houston, Lohse, Christine M. , Husmann, Douglas A. , Leibovich, Bradley C. , Gettman, Matthew T.

Mayo Clinic

Urology Practice | December 29, 2017 | Volume: 6 | Issue: 1 | Pages: 52-57

10.1016/j.urpr.2017.12.002 | PMID 37312349 Get It

Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM
Martinez‐Thompson, Jennifer M. , Snyder, Melissa R. , Ettore, Michael, McKeon, Andrew , Pittock, Sean J. , Roforth, Matthew M., Mandrekar, Jay , Mauermann, Michelle L. , Taylor, Bruce , Dyck, P. James B. , Windebank, Anthony J. , Klein, Christopher J. , Pittock, S J , Klein, Christopher J , McKeon, Andrew , Mauermann, Michelle L

Mayo Clinic

Muscle & Nerve | December 24, 2017 | Volume: 57 | Issue: 6 | Pages: 1000-1005

10.1002/mus.26051 | PMID 29272035 Get It

ABSTRACTIntroduction: Multifocal motor neuropathy (MMN) is a motor only, asymmetric onset neuropathy that is relatively treatment‐refractory compared with classic chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal acquired demyelinating sensory and motor (MADSAM) neuropathy. Methods: We reviewed 35 patients seropositive for GM1 (monosialo‐asialo [immunoglobulin M, IgM; immunoglobulin G, IgG]) and/or GD1b (disialo [IgG, IgM]) autoantibodies having MMN, classic CIDP, or MADSAM. Immune‐treatment responsiveness and clinical course was compared with antibody negative disease controls. Results: Seventy‐nine percent of seropositives with an initial diagnosis of MMN were immunotherapy responsive compared with 46% of seronegatives (P = 0.045). Eight ganglioside antibody positive MMN patients of 19 (42%) developed sensory findings consistent with MADSAM compared with 3 of 41 (7%) seronegative MMN patients (P = 0.003). MMN and MADSAM patients with ganglioside antibody positivity had more sustained treatment responses (P = 0.03). Discussion: Patients initially diagnosed with MMN seropositive for diverse GM1 autoantibodies appear more likely to have sustained treatment response and evolution to MADSAM. Muscle Nerve 57: 1000–1005, 2018
Sympathetic modulation of blood flow and O2 uptake in rhythmically contracting human forearm muscles
Joyner, M. J., Nauss, Lee A., Warner, Matthew A. , Warner, David O.

Mayo Clinic

American Journal of Physiology-Heart and Circulatory Physiology | December 21, 2017 | Volume: 263 | Issue: 4 | Pages: H1078-H1083

10.1152/ajpheart.1992.263.4.h1078 | PMID 1415755 Get It

This study tested the effects of sympathetically mediated changes in blood flow to active muscles on muscle O2 uptake (VO2) in humans. Four minutes of graded (15-80% of maximum voluntary contraction, MVC) rhythmic handgrip exercise were performed. Forearm blood flow (FBF) (plethysmography) and deep vein O2 saturation were measured each minute. Forearm O2 uptake was calculated using the Fick principle. In protocol 1, exercise was performed while supine and again while upright to augment sympathetic outflow to the active muscles. Standing reduced FBF at rest from 3.6 to 2.2 ml.100 ml-1.min-1 (P < 0.05). During light exercise (15-40% MVC) FBF was unaffected by body position. Standing reduced FBF (P < 0.05) from 36.0 to 25.2 ml.100 ml-1.min-1 and forearm VO2 from 38.2 to 28.1 ml.kg-1.min-1 during the final work load. In protocol 2, exercise was performed while supine before and after local anesthetic block of the sympathetic nerves to the forearm. Sympathetic block increased FBF at rest from 3.1 to 8.9 ml.100 ml-1.min-1 (P < 0.05), and FBF was higher during all work loads At 70-80% of MVC sympathetic block increased FBF from 35.4 to 50.7 ml.100 ml-1.min-1 (P < 0.05), and forearm VO2 from 45.5 to 54.2 ml.kg-1.min-1 (P < 0.05). These results suggest that in humans sympathetic nerves modulate blood flow to active muscles during light and heavy rhythmic exercise and that this restraint of flow can limit O2 uptake in muscles performing heavy rhythmic exercise.
Allograft-Prosthetic Composite Reconstruction for Massive Proximal Humeral Bone Loss in Reverse Shoulder Arthroplasty
Sánchez‐Sotelo, Joaquín , Wagner, Eric R. , Sim, Franklin H. , Sanchez-Sotelo, J. , Wagner, Eric R , Houdek, Matthew T.

Mayo Clinic

Journal of Bone and Joint Surgery | December 21, 2017 | Volume: 99 | Issue: 24 | Pages: 2069-2076

10.2106/jbjs.16.01495 | PMID 29257012 Get It

Background: Reverse total shoulder arthroplasty (RTSA) performed in the setting of massive proximal humeral bone loss often requires special reconstructive techniques. Restoration of the proximal part of the humerus with an allograft provides a number of theoretical benefits, including implant support, restoration of humeral length, deltoid tensioning, and an opportunity to repair the posterior aspect of the cuff to improve strength in external rotation and repair of the subscapularis to improve stability. However, reverse allograft-prosthesis composites (APCs) are costly, are technically demanding to use, and can be compromised by progressive allograft resorption. Methods: Between 2005 and 2012, the lead author used an APC reconstruction in 8 primary and 18 revision RTSAs (26 patients; mean age, 62 years; mean body mass index, 27.9 kg/m 2 ). The indications for the primary RTSAs included severe proximal humeral bone loss after trauma (n = 5) and tumor resection (n = 3). The indications in the revision setting were failed hemiarthroplasty (n = 11), anatomic total shoulder arthroplasty (n = 4), and reverse arthroplasty (n = 3). The most common reason for revision was instability (n = 10). A compression plate was used for graft-to-host fixation in all shoulders. Shoulders were assessed for pain, motion, American Shoulder and Elbow Surgeons (ASES) score, Simple Shoulder Test (SST) score, Neer score, revision or reoperation, radiographic evidence of graft union or resorption, and implant fixation. The mean duration of follow-up was 4 years (range, 2 to 10 years). Results: RTSA using an APC construct resulted in substantial improvements in pain scores (p < 0.0001), elevation (p < 0.0001), and external rotation (p = 0.004). With the numbers available, there were no significant differences in clinical outcomes between primary and revision cases. No patients required revision surgery for nonunion at the host-allograft junction. The mean time to union was 7 months, with 1 patient requiring bone-grafting for delayed union. Other complications included dislocation, deep infection, graft fracture, and periprosthetic fracture distal to the previous APC construct in 1 patient each. The 2 and 5-year revision-free survival rate was 96%. Conclusions: Reconstruction of proximal humeral bone loss with an APC at the time of primary or revision RTSA is safe and effective, with acceptable functional outcomes and complication rates. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.